Join us for Bioethics International’s 17th Annual Pharmaceutical Executive Roundtable on Ethics, Trust & Patient Centricity:
Defining Metrics for Success and the Role of the Good Pharma Scorecard
——————————— Apply to join us here———————————-
Bioethics International’s annual roundtable is the leading forum for senior leaders from across the healthcare ecosystem to develop metrics for and shape the future of ethics, transparency, access, and patient centricity in the pharmaceutical sector.
This year, we will also debut sector- and company-level performance trends from 3 new Good Pharma Scorecard (GPS) evaluations. Discussions inform agenda-setting and the development of metrics for the GPS.
Apply now to join the discussion. Attendance is limited to ensure participant voices can be heard. If your application is not successful this year, tickets will be refunded in full and we encourage you to apply again next year.
Session Topics
- Transparency and data sharing in clinical research
- Representation in clinical trial enrollment and data
- Access to medicines in LMICs hosting trials for FDA approvals
- Patient centricity: enterprise-level goals and metrics
When? June 8, 2026
- Roundtable: 8:00 AM – 5:00 PM
- Cocktails: 5:00 – 6:00 PM
- Speaker & BLF Member Dinner: 6:15 – 8:00 PM
Where? New York City
Additional details, including agenda and speakers will be shared soon. We encourage you to see last year’s agenda and speakers here.
Sponsors & Hosts
Bioethics International (BEI) – A 501(c)(3) public charity founded in 2005, advancing ethics, trust, patient centricity, and social responsibility in healthcare.
EY – Committed to building a better working world by fostering trust, delivering quality services, and developing leaders who create long-term value for stakeholders.
Scientific American – A leading authority on science and technology since 1845, shaping public understanding through contributions from world-renowned thinkers and Nobel laureates.
Yale Program for Biomedical Ethics – A multidisciplinary program spanning Yale’s schools and health system, dedicated to advancing education, research, and practice in medical ethics.
Good Pharma Scorecard (GPS) – A benchmark-driven index evaluating pharmaceutical companies on bioethics, social responsibility, and patient centricity, recognizing best practices and driving accountability across the sector.
Session 1 – Measuring Up: Transparency, Data Sharing, and the Path Forward for Clinical Research – “How Transparent Is Transparent Enough?
What constitutes meaningful transparency in clinical research today and how close is the pharmaceutical sector to delivering on that vision? This session will examine disclosure and data sharing goals and current progress against evolving expectations across the research lifecycle. The discussion will be anchored by the release of the latest Good Pharma Scorecard (GPS), pre-printed the morning of June 8, evaluating company and sector performance across trial registration, results reporting, FDAAA compliance, publication practices, and data sharing. Panelists from high-performing organizations (“bright spots”) will highlight strategies associated with their success. Looking ahead, the session will also revisit the GPS framework itself: Are current metrics still fit for purpose? What should were calibrate to better meet stakeholder priorities—such as returning data to trial participants, better real time benchmarking
Our Panelists
- Celine Enderlin, Global Head, Clinical Disclosure Office, Novartis
- Elizabeth Fox, Senior Vice President, Clinical Trials Research, Associate Director for Clinical Research, Comprehensive Cancer Center, St. Jude Children’s Research Hospital
- Kali Tarascavage, Clinical Transparency Lead, Otsuka Pharmaceutical
- Daniel Boisvert, Senior Director, Head of Data Stewardship, Biogen
- Joseph Ross, Professor of Medicine and of Public Health, Yale School of Medicine
- Vasee Moorthy, Senior Science and Strategy Advisor, World Health Organization
- Michelle Clausen, Head of Clinical Trial Disclosure and Expanded Access, Pfizer